Arcutis Biotherapeutics, Inc.
NASDAQArcutis Biotherapeutics filed Q1 2026 results after the close on May 6, delivering a split verdict that puts the stock's 13.5% short interest in an interesting position heading into the next trading session. The revenue number was the highlight. Q1 sales came in at $105.4 million, ahead of the $101.3 million consensus. That continues a remarkable commercial trajectory for Zoryve…
Snapshot as of 7 May 2026
Arcutis Biotherapeutics filed Q1 2026 results after the close on May 6, delivering a split verdict that puts the stock's 13.5% short interest in an interesting position heading into the next trading session. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ARQT — free to start on ORTEX.
Sign up for free →Open ARQT on ORTEX